|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.260 USD | -59.35% |
|
-.--% | - |
| 12-16 | Sonnet BioTherapeutics Holdings, Inc. Reports Earnings Results for the Full Year Ended September 30, 2025 | CI |
| 12-02 | Top Midday Decliners | MT |
Sales 2025 by Business Segment
Sales 2025 by Geography
Historical Breakdown of Revenue by Business Segments
Net Income: Breakdown by Business Segment
| Fiscal Period: September | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
Biological Products | ||||||||
Pharmaceuticals | 484K | 350K | 148K | 18.63K | 1M | |||
Total Assets | 28.99M | 5.83M | 5.43M | 2.77M | 14.88M | |||
Interest Expense | - | - | - | - | -556K | |||
Income Tax Expense | - | - | - | - | 218K | |||
CAPEX | -3.62K | - | - | - | - | |||
EBT | -24.98M | -29.72M | -18.83M | -7.44M | -15.79M | |||
D&A | 95.16K | 93.26K | 75.75K | 83.12K | 89.26K | |||
Operating Income | -25.09M | -29.67M | -18.79M | -11.85M | -15.84M | |||
Net Income | -24.98M | -29.72M | -18.83M | -7.44M | -16.01M |
Geographical Revenue Distribution History
| Fiscal Period: September | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
United States | 484K | 350K | 148K | 18.63K | 1M | |||
Total Assets | 28.99M | 5.83M | 5.43M | 2.77M | 14.88M | |||
Interest Expense | - | - | - | - | -556K | |||
Income Tax Expense | - | - | - | - | 218K | |||
D&A | 95.16K | 93.26K | 75.75K | 83.12K | 89.26K | |||
CAPEX | -3.62K | - | - | - | - | |||
Net Income | -24.98M | -29.72M | -18.83M | -7.44M | -16.01M | |||
EBT | -24.98M | -29.72M | -18.83M | -7.44M | -15.79M | |||
Operating Income | -25.09M | -29.67M | -18.79M | -11.85M | -15.84M |
- Stock Market
- Stocks
- SONN Stock
- Financials Sonnet Biotherapeutics
- Business Segments
Select your edition
All financial news and data tailored to specific country editions
